Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: To evaluate the prevalence of dysphagia in survivors of head and neck cancer (sHNC) and to identify the predictors contributing to the development of dysphagia.
Methods: We enrolled 62 sHNC in a cross-sectional study to check the prevalence of dysphagia in sHNC and to evaluate which factors were influencing the presence of this side effect. Besides dysphagia, sociodemographic and clinical characteristics, oral symptoms, maximal mouth opening (MMO), sleep quality and physical condition were evaluated, and a linear regression analysis was performed to verify which of these outcomes impact dysphagia.
Results: Among all the sHNC, 85.5% presented dysphagia. The linear regression analysis confirmed that 44.9% of the variance in dysphagia was determined by coughing, MMO and sleep quality, being MMO the most powerful predictor, followed by coughing and sleep quality.
Conclusion: Dysphagia affected the great majority of sHNC. Moreover, symptoms as coughing, reduced MMO and sleep disorders may act as predictors contributing to the development of dysphagia. Our results emphasize the importance of an early and proper identification of the symptoms as well as an adequate treatment strategy to address the cluster of symptoms that sHNC undergo.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10873441 | PMC |
| http://dx.doi.org/10.1007/s00520-024-08358-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identifying the optimal combinations of modifiable dementia risk factors to target in multidomain intervention - Three-year longitudinal findings from the Canadian longitudinal study on aging.
J Prev Alzheimers Dis
August 2025
Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario, Canada; Gait and Brain Lab, Parkwood Institute, Lawson Health Research Institute, London, Ontario, Canada; Department of Medicine, Division of Geriatric, Schulich Sc
Background: Recent multidomain prevention trials for dementia have shifted toward more targeted approaches, focusing on specific combinations of risk factors and interventions at certain times. However, the optimal combinations of modifiable risk factors that can be targeted to maximize intervention effect remain unclear. Identifying risk factor combinations with the highest prevalence and largest effect sizes can enhance efficiency of trial design.
View Article and Find Full Text PDFPerception of Lemborexant Effectiveness as Assessed by the Patient Global Impression-Insomnia Questionnaire.
Nat Sci Sleep
April 2025
Clinical Evidence Generation, Neurology and Deep Human Biology Learning, Eisai Inc., Nutley, NJ, USA.
Objective: Using data from a clinical study of lemborexant, evaluate responses to the Patient Global Impression-Insomnia (PGI-I) questionnaire, a simple 4-item questionnaire that assesses patients' perceptions of the effects of medication on sleep, which may help evaluate clinically meaningful changes from the patient's perspective.
Methods: Study E2006-G001-303, a 12-month, placebo (PBO)-controlled (first 6 months) Phase 3 study in adults with insomnia disorder, randomized subjects (1:1:1) to lemborexant 5 mg (LEM5; n=316), 10 mg (LEM10; n=315), or PBO (n=318). The second 6 months are not presented here.
Home-based rehabilitation versus centre-based programs in patients with temporomandibular disorders-a systematic review and meta-analysis.
J Oral Facial Pain Headache
March 2024
College of Sports Medicine and Physical Therapy, Beijing Sport University, 100084 Beijing, China.
To compare the effects of home-based rehabilitation and occlusal splints or centre-based rehabilitation in patients with temporomandibular joint disorders (TMD). A systematic review and meta-analysis. PubMed, Embase, Cochrane Library, Web of Science and ClinicalTrials.
View Article and Find Full Text PDF[Tirzepatide : overview of clinical studies SURPASS in type 2 diabetes and SURMOUNT in obesity].
Rev Med Liege
December 2024
Service de Diabétologie, Nutrition et Maladies métaboliques, CHU Liège, Belgique.
Tirzepatide is a unimolecular dual agonist of both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, which has been developed as once-weekly injection first for the treatment of type 2 diabetes (T2DM), then for the treatment of obesity. Because of the complementarity of action of the two incretins, tirzepatide showed, in a dose-dependent manner (5, 10 and 15 mg), a better efficacy (greater reduction in HbA1c and body weight) compared with placebo, semaglutide 1 mg, basal insulin and preprandial boluses of insulin lispro in six studies of the SURPASS programme. In the SURMOUNT programme, tirzepatide showed a marked reduction in body weight, never reached before with a drug, among people with obesity or overweight associated with complications linked to excess weight.
View Article and Find Full Text PDFEfficacy and safety of lemborexant in subjects with insomnia disorder receiving medications for depression or anxiety symptoms.
Neuropsychopharmacol Rep
March 2025
Eisai Ltd., Hatfield, UK.
Article Synopsis
- The study aimed to investigate the effects of lemborexant (LEM) on individuals with insomnia who also experience mild depression or anxiety symptoms.
- Over a 12-month period, 61 subjects out of 949, who were using medications for depression/anxiety, were evaluated for changes in sleep quality and related measures while being treated with either LEM or a placebo.
- Results showed that while LEM was effective for improving sleep metrics in the subpopulation, the placebo response was stronger, resulting in a smaller effect size for LEM compared to the overall study population, but no new safety concerns were identified.